Vaxcyte executive sells 2,715 shares in planned trades

EVP and COO Jim Wassil disclosed pre-planned share sales and RSU tax-withholding share surrenders in September 2026 for Vaxcyte, Inc.

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) executive Jim Wassil, EVP, Chief Scientific Officer and COO, reported selling a total of 2,715 shares of common stock in open-market transactions on September 4 and 9, 2026, at weighted-average prices around $61.16 and $59.52, respectively, under a Rule 10b5-1 trading plan adopted on December 9, 2025. On September 8, 2026, 5,459 shares were surrendered to the issuer to cover tax withholding obligations upon RSU vesting.

Insider Trade Summary

Net Seller: 2,715 shares

Net Sell 3 txns

Insider Wassil Jim

Role EVP, Chief Scientific Ofc, COO

Sold 2,715 shs ($164K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F4	1,334	$59.521	$79K
Tax Withholding	Common Stock F3	5,459	$60.36	$330K
Sale	Common Stock F1, F2	1,381	$61.16	$84K

Holdings After Transaction: Common Stock — 145,435 shares (Direct)

Footnotes (4)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
2. F2. The price reported is a weighted-average price. The shares were sold at prices ranging from $60.95 to $61.57. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. F3. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
4. F4. The price reported is a weighted-average price. The shares were sold at prices ranging from $59.155 to $60.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold (open market): 2,715 shares Sale price September 4, 2026: $61.16 per share (weighted-average) Sale price September 9, 2026: $59.521 per share (weighted-average) +2 more

5 metrics

Shares sold (open market) 2,715 shares Total common shares sold on September 4 and 9, 2026

Sale price September 4, 2026 $61.16 per share (weighted-average) Common stock sale with prices from $60.95 to $61.57

Sale price September 9, 2026 $59.521 per share (weighted-average) Common stock sale with prices from $59.155 to $60.12

Shares surrendered for tax withholding 5,459 shares Shares delivered to issuer on September 8, 2026 to cover RSU tax obligations

Rule 10b5-1 plan adoption date December 9, 2025 Pre-arranged trading plan governing the reported sales

Key Terms

Rule 10b5-1 trading plan, weighted-average price, RSUs, tax withholding obligations

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported is a weighted-average price. The shares were sold at prices"

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

RSUs financial

"tax withholding obligations realized upon the vesting of RSUs."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax withholding obligations financial

"Represents shares surrendered to the Issuer to cover applicable tax withholding obligations"

FAQ

What insider transactions did PCVX executive Jim Wassil report in this Form 4?

Jim Wassil reported two open-market sales totaling 2,715 shares of Vaxcyte common stock on September 4 and 9, 2026, plus a separate disposition of 5,459 shares on September 8, 2026, surrendered to Vaxcyte to cover tax withholding upon RSU vesting.

At what prices were the PCVX shares sold by Jim Wassil in September 2026?

The Form 4 reports weighted-average prices: about $61.16 per share on September 4, 2026, with individual sale prices from $60.95 to $61.57, and about $59.52 per share on September 9, 2026, with prices from $59.155 to $60.12.

Were Jim Wassil’s PCVX share sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states that the share sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the trades were pre-arranged under that plan.

Why did Jim Wassil surrender 5,459 PCVX shares on September 8, 2026?

The Form 4 explains that 5,459 shares of Vaxcyte common stock were surrendered to the issuer on September 8, 2026 to cover applicable tax withholding obligations realized upon the vesting of RSUs.

How many PCVX shares did Jim Wassil sell versus surrender for taxes?

According to the Form 4 summary, Jim Wassil sold 2,715 shares of Vaxcyte common stock in open-market transactions and separately 5,459 shares were disposed of to satisfy tax withholding obligations related to RSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 05:47 PM Accepted by SEC EDGAR 09/09/2026 - 05:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wassil Jim

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Ofc, COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2026		S(1)		1,381(2)	D	$61.16	152,228	D
Common Stock	09/08/2026		F		5,459(3)	D	$60.36	146,769	D
Common Stock	09/09/2026		S(1)		1,334(4)	D	$59.521	145,435	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

2. The price reported is a weighted-average price. The shares were sold at prices ranging from $60.95 to $61.57. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

4. The price reported is a weighted-average price. The shares were sold at prices ranging from $59.155 to $60.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

	Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)